There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| Ask | Qty | Orders |
|---|---|---|
| 1701.9 | 1 | 144 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
Quarterly Revenue,rose 7.95% YoY to ₹100.56 Cr. Its sector's average revenue growth YoY for the quarter was 12.57%.Interest Coverage Ratio,is 105.45, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).Debt to Equity Ratio,is zero as the company is debt-free.
Novartis India Limited is a pharmaceutical company. The business operations of the Company include Pharmaceuticals Generic over the counter (OTC) and Animal Health. The Pharmaceuticals segment consists of a portfolio of prescription medicines which are provided to patients through healthcare professionals.
The Generics segment consists of retail generics products. The Generics segment’s unit primarily focuses on the therapeutic segments such as Anti-TB Anti-DUB (Gynaecology) Anti-histamines Antibiotics Anti-ulcerants Anti-diabetes and Cardiovascular. The Animal Health segment has a presence primarily in the cattle and poultry market segments.
The OT C segment is mainly in the vitamins minerals and nutritional supplements (VMS) and cough cold and allergy (CoCoA) market segments. During the fiscal year ended March 31 2012 it introduced Enplus product in the Poultry segment and Dexbov Antifur Vayuhara Vetimam and Feedavit in the Cattle segment..The company also in the business activities of OTC Generics Animal Health Pharmaceuticals.
For Q4 FY26, Novartis India Ltd reported: Revenue (Net Sales): ₹905.50 Cr - Up 5.41% year-on-year from ₹859.00 Cr in Q3 FY26. Net Income (PAT): ₹252.50 Cr - Up 56.93% year-on-year from ₹160.90 Cr in Q3 FY26.
The intraday high for Novartis India Ltd on the NSE today (21 Jul 2026) was ₹1,713.00. This compares to the 52-week high of ₹1,723.00 recorded on 14 Jul 2026. Today's high was -0.58% below the 52-week high.
The intraday low for Novartis India Ltd on the NSE today was ₹1,552.00. The stock's 52-week low stands at ₹950.00, recorded on 24 Apr 2026. Today's low is 63.37% above the 52-week low, indicating the stock is trading well above its yearly lows.
As of 21 Jul 2026, the share price of Novartis India Ltd is ₹1,699.90 on the NSE and ₹1,697.00 on the BSE. The stock opened at ₹1,676.20, touched a high of ₹1,713.00 and a low of ₹1,552.00 during today's session.
Over the last 6 months, Novartis India Ltd has given a return of 67.55%. The stock was priced at ₹N/A on N/A and has risen to ₹1,699.90 as of 21 Jul 2026, a change of ₹N/A per share.
Novartis India Ltd has delivered 67.55% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹1,723.00 on 14 Jul 2026 and a 52-week low of ₹950.00 on 24 Apr 2026. It is currently trading at ₹1,699.90 as of 21 Jul 2026.
The all-time high (ATH) for Novartis India Ltd was ₹1,667.90, recorded on 20 Jul 2026. At the current price of ₹1,699.90, the stock is trading -1.92% below its all-time high. The all-time low recorded was ₹546.00 on 26 Mar 2021.
Novartis India Ltd has delivered a 66.71% absolute return over the past 5 years, equivalent to a CAGR of 10.76% per annum. The stock was priced at ₹1,019.67 in Jul 2021 and has risen to ₹1,699.90 as of 21 Jul 2026. An investment of ₹1,00,000 in Novartis India Ltd five years ago would be worth ₹1,66,710.00 today.
No,Novartis India Ltd has not declared any dividend over the past 5 years. The company paid a total dividend of 107.50 per share between FY2022 and FY2026, with the most recent dividend of ₹25.00 per share for May 25, with an ex-dividend date of 23 Jul 2025. At the current market price of ₹1,699.90, the trailing dividend yield of Novartis India Ltd stands at 50.00%.
Novartis India Ltd has delivered a return of 68.66% over the last 3 months. The stock was trading at ₹988.90 on 21 Apr 2026 and is currently at ₹1,699.90 as of 21 Jul 2026, reflecting a Gain of ₹711.00 per share over this period.
